Register entry
Ocular Therapeutix, Inc.
- Registered sites
- 1
- Drug products
- 1
- Live patents
- 5
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Finished drug manufacture
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Ocular Therapeutix, Inc. | Bedford, MAUnited States | Finished drug manufacture | 3008477155 |
Exclusivity
Patents
5Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| DEXTENZA | DEXAMETHASONE | Feb 2030 |
| DEXTENZA | DEXAMETHASONE | May 2030 |
| DEXTENZA | DEXAMETHASONE | Oct 2036 |
| DEXTENZA | DEXAMETHASONE | Nov 2037 |
| DEXTENZA | DEXAMETHASONE | Apr 2041 |
Catalogue
Marketed products
1Showing 1 of 1.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| DEXTENZA | dexamethasone | INSERT | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.